The Developmental Research Program (DRP) is designed to provide funding to initiate promising translational studies with a focus on brain tumors. High priority will be given to projects that will generate clinically-relevant hypotheses aimed at reducing the morbidity or mortality of brain tumors or improving the quality of life of patients with brain tumors. At least annually, proposals for innovative translational brain tumor research will be solicited throughout all institutions in the Texas Medical Center. It is anticipated that some applicants will be without extensive experience in preparing successful research proposals; therefore, the DRP Co-Directors will help investigators formulate specific aims and research plans that are translational in nature, with realistic and appropriate budgets. Thus, in addition to developing promising research projects for the SPORE program, the DRP will also be a major educational activity that will further enhance the initiation and development of innovative translational research concepts in brain cancer. The SPORE Executive Committee will screen proposals for appropriate SPORE qualifications using objective criteria. The selected proposals will then undergo scientific review and prioritization by members of the SPORE External Advisory Board;final selection of the research projects to be funded will be made on the basis of these reviews. A two-year funding period will be allowed, with allocation of funds for the second year to be made after satisfactory review of a written progress report from the awardee. Additional funding may be granted, if it is felt that an additional year of work will lead to independent peer-reviewed funding and/or lead to significant enhancement in diagnosis or treatment of brain tumors;requests for this additional funding will be very carefully reviewed by the SPORE Executive Committee and External Advisory Board. As part of our continuing efforts to expand brain tumor research at The University of Texas M. D. Anderson Cancer Center and in anticipation of this SPORE application, developmental research projects were solicited;the four projects considered to be of highest potential and consistent with the translational focus of the SPORE are included here and represent those that will be considered for funding to begin in Year 1 of the SPORE program. These projects illustrate the breadth and depth of interest in brain tumor translational research at our institution.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Lu, Sean; Wang, Yugang (2018) Nonmetabolic functions of metabolic enzymes in cancer development. Cancer Commun (Lond) 38:63
Qiao, Yang; Gumin, Joy; MacLellan, Christopher J et al. (2018) Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection. Nanotechnology 29:165101
Zinn, Pascal O; Singh, Sanjay K; Kotrotsou, Aikaterini et al. (2018) A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res 24:6288-6299
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Mostovenko, Ekaterina; Végvári, Ákos; Rezeli, Melinda et al. (2018) Large Scale Identification of Variant Proteins in Glioma Stem Cells. ACS Chem Neurosci 9:73-79
Chen, Zhihua; Morales, John E; Guerrero, Paola A et al. (2018) PTPN12/PTP-PEST Regulates Phosphorylation-Dependent Ubiquitination and Stability of Focal Adhesion Substrates in Invasive Glioblastoma Cells. Cancer Res 78:3809-3822
Wang, Yugang; Xia, Yan; Lu, Zhimin (2018) Metabolic features of cancer cells. Cancer Commun (Lond) 38:65
Noh, Hyangsoon; Zhao, Qingnan; Yan, Jun et al. (2018) Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185
Lee, Jong-Ho; Liu, Rui; Li, Jing et al. (2018) EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell 70:197-210.e7
Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427

Showing the most recent 10 out of 232 publications